Interview: Steve Bates – CEO, BioIndustry Association (BIA), UK
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
Address: 7th Floor, Southside
105 Victoria Street
London
SW1E 6QT
UK
Tel: +44 (0)20 7630 2180
Web: http://www.bioindustry.org/home/
The UK BioIndustry Association, the BIA, is the trade association for innovative enterprises involved in UK bioscience. Members include start-up, emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.
The BIA works to further the interests of members and the industry – nationally and internationally. Our heritage of innovation, enterprise and success dates back to our founding over 20 years ago.
Influencing Progress
Bioscience is a national priority for the UK. The BIA works to encourage and promote a financially sound and thriving bioscience sector within the UK economy.
Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, to help enable our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
Lobbying is a core BIA strength. We provide a strong, unified, relentless voice for bioscience to stakeholders — including government, politicians, the media and patient advocate groups — to address the critical issues our members face and to push for progress. We educate policy makers about the needs of our members and advocate for legislation and policies essential to their growth and success.
Enabling Connections
Collaboration is key to moving bioscience forward. To support and enhance collaboration, the BIA brings together organisations from across the life sciences industry. This includes service providers, valued not only for the vital functions they serve in the sector, but also for their business acumen, expert guidance and industry connections.
The BIA hosts events throughout the year where members and others from the sector can learn, discuss, debate and network.
BIA Advisory Committee meetings connect peer groups to engage in debate and develop solutions to shared issues and challenges.
The BIA also keeps members connected and updated via regular communications. In addition, the BIA provides a host of other business development and business support services to enhance the value of membership. We facilitate introductions to other BIA members, provide meeting spaces at our central London office, offer member-only discounts to BIA and selected third-party events and also with suppliers.
In fulfilling its mission, the BIA aims to:
1 Offer a wide range of member services and benefits to the satisfaction of the membership
2 Represent the needs of the industry and its members on important issues
3 Promote best practice within the industry
4 Facilitate industry growth and maturity, positioning the UK as a leading world player in bioscience
5 Campaign for the best possible environment for innovative bioscience research
6 Communicate the benefits of innovative bioscience technologies
7 Maintain its role as the Association of choice for membership representation and communication on innovative bioscience issues
The BIA operates an active public affairs programme, a well-developed conference and and seminar programme, trade missions, regular publications for internal and external audiences, plus a series of committees whose interests range from regulatory affairs and intellectual property to personnel and finance and taxation. Networking and technology-transfer opportunities for members and others with an interest in the sector ensure that every avenue is explored in the support of UK bioscience.
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug…
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how…
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Recently appointed CEO of Health Innovation Manchester, Ben Bridgewater explains the organization’s goal of improving the lives of the people of Greater Manchester by ensuring a constant pipeline of innovation,…
Taking the conversation beyond Brexit, His Excellency Lars Thuesen, ambassador of Denmark to the UK, highlights the solid ties that have linked both countries since the Danes invaded the island…
The Ambassador of Switzerland to the UK, Alexandre Fasel, discloses what has been achieved so far with the ‘Mind the Gap’ strategy, aimed at safeguarding British-Swiss economic and business…
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short…
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
See our Cookie Privacy Policy Here